|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2005-04-11 |
A Phase 1, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects
The purpose of this study is to assess the safety and tolerability of ocular administration of Topical Interleukin-1-Receptor Antagonist in healthy volunteers. Additionally, the PK of Interleukin-1-Receptor Antagonist will be assessed.
100 项与 成都诺迪康生物制药有限公司 相关的临床结果
0 项与 成都诺迪康生物制药有限公司 相关的专利(医药)
100 项与 成都诺迪康生物制药有限公司 相关的药物交易
100 项与 成都诺迪康生物制药有限公司 相关的转化医学